Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries ; volume:30 ; number:1 ; day:7 ; month:12 ; year:2023 ; pages:1-15 ; date:12.2023
Middle East current psychiatry ; 30, Heft 1 (7.12.2023), 1-15, 12.2023
- Urheber
-
Ahmed, Nahida Nayaz
Albishi, Faisal
Khan, Suhail A.
Alsayegh, Ammar
Stip, Emmanuel
Makhoul, Samer
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43045-023-00369-3
- URN
-
urn:nbn:de:101:1-2024020512230078354549
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2500, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ahmed, Nahida Nayaz
- Albishi, Faisal
- Khan, Suhail A.
- Alsayegh, Ammar
- Stip, Emmanuel
- Makhoul, Samer
- SpringerLink (Online service)
Ähnliche Objekte (12)
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Personalized use of ketamine and esketamine for treatment-resistant depression
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Personalized use of ketamine and esketamine for treatment-resistant depression
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant
Correction to: Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials
Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies
Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study
Personalized use of ketamine and esketamine for treatment-resistant depression
Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial
Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant